Study Progress
Patient enrollment in COMPPARE is now closed. As of 10/31/22, COMPPARE reported a final enrollment of 600 RCT proton participants, 900 pragmatic proton participants, and 1024 photon participants, for a total of 2,524 patients. …
Patient enrollment in COMPPARE is now closed. As of 10/31/22, COMPPARE reported a final enrollment of 600 RCT proton participants, 900 pragmatic proton participants, and 1024 photon participants, for a total of 2,524 patients. …
PCORI Acknowledgement Research reported in this study website was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-2017C1-0422). PCORI Disclaimer The views, statements, and opinions presented in this study website are solely the responsibility of the author(s) and do not necessarily represent the views of the…
Day-to-day administration, communications, project management, financial management, and clinical coordination will be managed by the following Coordinating Center staff: Kari Bastow University of Florida Contracting Coordinator Robin Cacchio, RN, CCRP University of Florida Proton Therapy Institute Director of Research Services…
The Patient and Caregiver Stakeholders are a diverse group of prostate cancer survivors and caregivers who have worked with the PI, co-PI, and co-investigators to develop this study and help to monitor our progress through quarterly web conferences. Members include: Scott Cielewich Rui Dos Santos (Minority Engagement Group Member) Thomas…
The COMPPARE Consortium is proud to partner with the following organizations: 100 Black Men of America 100 Black Men of America’s local chapters prepare young men and women to realize their highest potential.
The site principal investigators, co-investigators, and researchers will be responsible for supervision of research staff, protocol development, patient accrual, initial data submission review, analysis of outcomes, and generation of PCORI milestone reports. Mark Artz, PhD UF Health Proton Therapy Institute Physics Co-Coordinator…
The Advanced Technology Consortium (ATC) will provide an informatics infrastructure and quality assurance process to support the submission, review, and analysis of volumetric imaging and treatment planning data for the COMPPARE study. Leadership of the ATC includes: Walter Bosch, DSc…
While the PI will have oversight for the design and conduct of the trial, the Executive Board will review all aspects of the study, accrual progress, conflicts, and resolutions, and will provide guidance to the PI. Executive Board members include: Nancy Mendenhall, MD University of…
A Message from Dr. Nancy Mendenhall As we continue our important work for COMPPARE, we have joined national organizations in developing procedures to treat patients with prostate cancer and other malignancies safely during the COVID-19 outbreak. In addition, we are collaborating with our sites to strengthen their…